Author:
Lopez-Bujanda Zoila A.,Hadavi Shawn H.,Ruiz De Porras Vicenç,Martínez-Balibrea Eva,Dallos Matthew C.
Reference208 articles.
1. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer;Agarwal;Future Oncology (London),2022
2. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021);Agarwal;The Lancet Oncology,2022
3. Interleukin-8 in cancer pathogenesis, treatment and follow-up;Alfaro;Cancer Treatment Reviews,2017
4. Clinical significance of defective dendritic cell differentiation in cancer;Almand;Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,2000
5. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers;Anandasabapathy;Bone Marrow Transplantation,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chemokine receptors in COVID-19 infection;International Review of Cell and Molecular Biology;2024